Search Results 61-70 of 21205 for Inhibition

  1. A Study Using Targeted Inhibitors to Treat Specific Tumor Mutations in Patients with Meningiomas - Mayo Clinic

    ... inhibitor GSK2256098 work in treating patients with meningiomas that may have gotten bigger or grew back after treatment. Vismodegib and FAK inhibitor ...

  2. A Study Comparing the Safety of Tofacitinib versus Tumor Necrosis Factor Inhibitor in Patients with Rheumatoid Arthritis - Mayo Clinic

    The purpose of this post-marketing study is to compare the safety of tofacitinib versus tumor necrosis factor inhibitor with respect to major cardiovascular ...

  3. Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) - Mayo Clinic

    ... Inhibitor Associated Musculoskeletal Symptoms (AIMSS). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease ...

  4. Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash - Mayo Clinic

    We would like to see if use of topical ketoconazole will improve rashes in patients with EGFR inhibitor-induced rash. Participation eligibility. Participant ...

  5. Hormone therapy for breast cancer - Mayo Clinic

    Aromatase inhibitors are medicines that reduce the amount of estrogen in the body. This medicine deprives breast cancer cells of the hormones they need to ...

  6. A Study to Assess the MEK Inhibitor Mirdametinib (PD-0325901) in Patients with Neurofibromatosis Type 1 Associated Plexiform Neurofibromas - Mayo Clinic

    A Study to Assess the MEK Inhibitor Mirdametinib (PD-0325901) in Patients with Neurofibromatosis Type 1 Associated Plexiform Neurofibromas · Share · Facebook ...

  7. Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies - Mayo Clinic

    The purpose of this study is to demonstrate the effectiveness of neflamapimod, compared to placebo, as a treatment for DLB, as assessed by the Clinical Dementia ...

  8. 5-strain Probiotic Formulation in Hormone Receptor-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss - Mayo Clinic

    5-strain Probiotic Formulation in Hormone Receptor-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss ... inhibitors after 3- and 12-month ...

  9. BCL2 Inhibitor Venetoclax With Daratumumab-Lenalidomide-Dexamethasone Or Venetoclax-Rd for Newly Diagnosed Multiple Myeloma - Mayo Clinic

    BCL2 Inhibitor Venetoclax With Daratumumab-Lenalidomide-Dexamethasone Or Venetoclax-Rd for Newly Diagnosed Multiple Myeloma · More about research at Mayo Clinic.

  10. Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma - Mayo Clinic

    Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma. Print details. Share ...